tirzepatide clinical trial New trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Reduction of prevalence of patients

The American College of Physicians emphasizes shared decision-making in obesity management, making open communication about treatment experience, including hunger, an essential component of successful outcomes with medications like Zepbound

Gclc f/f mice were generated as described 30 and crossed with the Rosa26-CreERT2 mouse strain (Jackson Labs, #008463) or Nrf2 f/f mouse strain (Jackson Labs, #025433)

21 Savage 'Bartier Cardi'"

A 70mg Glow formulation supplied in a pre-filled research device, provided exclusively for controlled laboratory R&D applications

The human MOTS-c data are much weaker and are mostly focused on biomarker research rather than treatment trials